Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
CANCER:
Mediastinal B Cell Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (832
)
Diffuse Large B Cell Lymphoma (295
)
Mantle Cell Lymphoma (101
)
Small Lymphocytic Lymphoma (98
)
T Cell Non-Hodgkin Lymphoma (79
)
Follicular Lymphoma (73
)
Lymphoplasmacytic Lymphoma (58
)
Peripheral T-cell Lymphoma (48
)
Marginal Zone Lymphoma (33
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (12
)
Non-Hodgkin’s Lymphoma (832
)
Diffuse Large B Cell Lymphoma (295
)
Mantle Cell Lymphoma (101
)
Small Lymphocytic Lymphoma (98
)
T Cell Non-Hodgkin Lymphoma (79
)
Follicular Lymphoma (73
)
Lymphoplasmacytic Lymphoma (58
)
Peripheral T-cell Lymphoma (48
)
Marginal Zone Lymphoma (33
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (12
)
›
Associations
(8)
Heatmap
News
Twitter
Trials
Reset Filters
Veri cancer hierarchy
x
x
x
x
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
MYC overexpression
Mediastinal B Cell Lymphoma
MYC overexpression
Mediastinal B Cell Lymphoma
lisocabtagene maraleucel
Resistant: C3 – Early Trials
lisocabtagene maraleucel
Resistant
:
C3
lisocabtagene maraleucel
Resistant: C3 – Early Trials
lisocabtagene maraleucel
Resistant
:
C3
EZH2 overexpression
Mediastinal B Cell Lymphoma
EZH2 overexpression
Mediastinal B Cell Lymphoma
lisocabtagene maraleucel
Resistant: C3 – Early Trials
lisocabtagene maraleucel
Resistant
:
C3
lisocabtagene maraleucel
Resistant: C3 – Early Trials
lisocabtagene maraleucel
Resistant
:
C3
MYC rearrangement
Mediastinal B Cell Lymphoma
MYC rearrangement
Mediastinal B Cell Lymphoma
rituximab
Sensitive: C3 – Early Trials
rituximab
Sensitive
:
C3
rituximab
Sensitive: C3 – Early Trials
rituximab
Sensitive
:
C3
BCL6 rearrangement
Mediastinal B Cell Lymphoma
BCL6 rearrangement
Mediastinal B Cell Lymphoma
rituximab
Sensitive: C3 – Early Trials
rituximab
Sensitive
:
C3
rituximab
Sensitive: C3 – Early Trials
rituximab
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
